Reply - 28/04/12
H.A.S. was supported in part by AI-044236 from the National Institute of Allergy and Infectious Diseases/National Institutes of Health. |
|
Disclosure of potential conflict of interest: H. A. Sampson is a consultant for Allertein Therapeutics, LLC; is on the advisory board for ImmusanT and Novartis; has received research support from the Food Allergy Initiative (FAI) and the National Institute of Allergy and Infectious Diseases; is a consultant and scientific advisor for the FAI; is a medical advisor for the Food Allergy and Anaphylaxis Network; is a scientific advisor for the University of Nebraska FARRP; and is 45% owner of Herbal Springs, LLC. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 129 - N° 5
P. 1422-1423 - mai 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?